Dashboard
Manage Tickers

ATOS ATOSSA THERAPEUTICS, INC.

Nasdaq atossatherapeutics.com


$ 0.88 $ 0.00 (0.35 %)    

Thursday, 30-Oct-2025 17:39:11 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 633.20 $ -9.72 (-1.53 %)
DIA $ 475.83 $ -1.36 (-0.29 %)
SPY $ 684.43 $ -7.56 (-1.1 %)
TLT $ 90.42 nm (nm)
GLD $ 371.67 $ 7.13 (1.96 %)
$ 0.88
$ 0.87
$ 0.86 x 1,017
$ 0.96 x 940
-- - --
$ 0.55 - $ 1.66
556,490
na
113.67M
$ 1.89
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-25-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 04-01-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-22-2023 12-31-2022 10-K
12 11-07-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-13-2021 06-30-2021 10-Q
18 05-14-2021 03-31-2021 10-Q
19 03-31-2021 12-31-2020 10-K
20 11-13-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 05-13-2020 03-31-2020 10-Q
23 03-26-2020 12-31-2019 10-K
24 11-13-2019 09-30-2019 10-Q
25 08-13-2019 06-30-2019 10-Q
26 05-13-2019 03-31-2019 10-Q
27 03-28-2019 12-31-2018 10-K
28 11-14-2018 09-30-2018 10-Q
29 08-13-2018 06-30-2018 10-Q
30 05-14-2018 03-31-2018 10-Q
31 03-08-2018 12-31-2017 10-K
32 11-13-2017 09-30-2017 10-Q
33 08-14-2017 06-30-2017 10-Q
34 05-11-2017 03-31-2017 10-Q
35 03-16-2017 12-31-2016 10-K
36 11-14-2016 09-30-2016 10-Q
37 08-12-2016 06-30-2016 10-Q
38 05-05-2016 03-31-2016 10-Q
39 03-30-2016 12-31-2015 10-K
40 11-12-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

atossa-highlights-enrollment-progress-and-biomarker-strategy-for-recast-trial-aiming-to-de-risk-development-of-z-endoxifen-for-ductal-carcinoma-in-situ
Atossa Highlights Enrollment Progress And ...
10/21/2025 12:17:57

Investor-focused update underscores enrollment momentum, biomarker strategy, and near-term data readouts designed to de-risk de...

atossa-therapeutics-appoints-mark-daniel-as-cfo
Atossa Therapeutics Appoints Mark Daniel A...
10/14/2025 12:15:09

25+ year life-sciences finance leader brings revenue-forecasting rigor, public-company controls, and capital-markets experience...

ascendiant-capital-maintains-buy-on-atossa-therapeutics-raises-price-target-to-775
Ascendiant Capital Maintains Buy on Atossa...
09/22/2025 09:28:37

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target fro...

atossa-therapeutics-announces-it-has-requested-a-type-c-meeting-with-the-fda-to-discuss-a-regulatory-strategy-to-accelerate-the-development-of-low-dose-endoxifen-for-reducing-breast-cancer-risk
Atossa Therapeutics Announces It Has Reque...
09/08/2025 12:36:20

Atossa Therapeutics, Inc. (NASDAQ:ATOS, ", Atossa", or the ", Company", ))) announced today it has requested a ...

atossa-therapeutics-selects-psi-to-manage-fda-guided-z-endoxifen-dose-ranging-study-in-metastatic-breast-cancer-ahead-of-phase-3
Atossa Therapeutics Selects PSI To Manage ...
08/20/2025 12:31:56

Monotherapy Phase 2 study designed with FDA input; IND expected in Q4 2025Topline results anticipated in 2026 Positions Atossa ...

atossa-therapeutics-q2-eps-007-misses-006-estimate
Atossa Therapeutics Q2 EPS $(0.07) Misses ...
08/12/2025 12:38:44

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of...

atossa-therapeutics-announces-fda-feedback-on-proposed-dose-optimization-trial-of-z-endoxifen-clinical-program-in-erher2--metastatic-breast-cancer
Atossa Therapeutics Announces FDA Feedback...
07/29/2025 11:46:15

ascendiant-capital-maintains-buy-on-atossa-therapeutics-raises-price-target-to-75
Ascendiant Capital Maintains Buy on Atossa...
06/06/2025 10:40:29

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target fro...

this-excelerate-energy-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-thursday
This Excelerate Energy Analyst Begins Cove...
06/05/2025 19:17:32

craig-hallum-initiates-coverage-on-atossa-therapeutics-with-buy-rating-announces-price-target-of-4
Craig-Hallum Initiates Coverage On Atossa ...
06/05/2025 17:15:59

Craig-Hallum analyst Albert Lowe initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Buy rating and announces Pri...

atossa-therapeutics-reports-full-results-from-phase2-eop-substudy-within-ispy2-trial-evaluating-lowdose-oral-zendoxifen-as-neoadjuvant-treatment-in-20-women-with-stageiiiii-er-her2negative-breast-cancer
Atossa Therapeutics Reports Full Results F...
05/14/2025 12:19:03

Feasibility endpoint achieved; rapid Ki‑67 suppression and substantial MRI‑confirmed tumor shrinkage observed with favorable sa...

atossa-therapeutics-q1-eps-005-beats-006-estimate
Atossa Therapeutics Q1 EPS $(0.05) Beats $...
05/13/2025 12:06:38

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $...

atossa-therapeutics-awarded-us-patent-no-12281056-including-58-claims-covering-various-formulations-for-its-z-endoxifen-portfolio
Atossa Therapeutics Awarded U.S. Patent No...
04/30/2025 12:49:50

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company...

atossa-therapeutics-outlines-framework-for-pioneering-phase-3-clinical-study-titled-smart-20-at-aacr-2025
Atossa Therapeutics Outlines Framework For...
04/29/2025 12:52:23

Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company...

atossa-therapeutics-uspto-grants-new-patent-directed-to-enteric-oral-formulations-comprising-z-endoxifen-as-well-as-methods-of-treating-subjects-with-oral-formulations
Atossa Therapeutics: USPTO Grants New Pate...
04/22/2025 12:46:52

SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company")...

ascendiant-capital-maintains-buy-on-atossa-therapeutics-raises-price-target-to-725
Ascendiant Capital Maintains Buy on Atossa...
04/21/2025 10:08:07

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target fro...

atossa-therapeutics-files-petition-for-post-grant-review-against-company-intas-pharmaceuticals-files-petition-for-inter-partes-review-against-company-to-contest-pgr-and-lpr-petitions
Atossa Therapeutics Files Petition For Pos...
04/07/2025 20:21:21

-SEC Filing

hc-wainwright--co-reiterates-buy-on-atossa-therapeutics-maintains-7-price-target
HC Wainwright & Co. Reiterates Buy on Atos...
03/26/2025 10:03:51

HC Wainwright & Co. analyst Emily Bodnar reiterates Atossa Therapeutics (NASDAQ:ATOS) with a Buy and maintains $7 price ...

atossa-therapeutics-fy-2024-gaap-eps-020-beats-022-estimate-cash-711m
Atossa Therapeutics FY 2024 GAAP EPS $(0.2...
03/25/2025 12:05:40

Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $...

earnings-scheduled-for-march-25-2025
Earnings Scheduled For March 25, 2025
03/25/2025 08:32:09

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION